Phase
Condition
N/ATreatment
DAOIB
Clinical Study ID
Ages 18-100 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
"post-COVID-19 condition" defined by WHO (symptoms present at three months afterSARS-CoV-2 infection and last for at least 2 months which cannot be explained by analternative diagnosis)(Cabrera Martimbianco, Pacheco et al. 2021) and COVID-inducedcognitive impairments
physically healthy and have all laboratory assessments (including urine/bloodroutine, biochemical tests, and electrocardiograph) within normal limits
have sufficient education to communicate effectively and are capable of completingthe assessments of the study
Exclusion
Exclusion Criteria:
history of significant cerebrovascular disease
Hachinski Ischemic Score > 4
major neurological, psychiatric or medical conditions other than long COVID-inducedcognitive impairments
memantine use (memantine is an NMDAR partial antagonist)
substance (including alcohol) abuse or dependence
delusion, hallucination or delirium symptoms
severe visual or hearing loss
inability to follow the protocol
Study Design
Connect with a study center
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung, 886
TaiwanActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.